Sieving treatment biomarkers from blood gene-expression profiles: A pharmacogenomic update on two types of multiple sclerosis therapy

Pharmacogenomics

Volumn 12, Issue 3, 2011, Pages 423-432

  Goertsches, Robert H ^a   Zettl, Uwe K ^a   Hecker, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

mechanism of action; molecular biomarker; multiple sclerosis; therapy n transcriptomics

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; DRUG ANTIBODY; DRUG RECEPTOR; GLATIRAMER; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON; RITUXIMAB;

ADAPTIVE IMMUNITY; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DNA MICROARRAY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PROGNOSIS; RELAPSE; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TREATMENT RESPONSE;

BIOMARKERS, PHARMACOLOGICAL; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; IMMUNOTHERAPY; INTERFERON-BETA; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; PROGNOSIS; RISK ASSESSMENT;

EID: 79953238968     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.190     Document Type: Article

References (81)

1. Graber JJ, McGraw CA, Kimbrough D et al.: Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin. Neurol. Neurosurg. 112(7), 583-591 (2010).
2. Aktas O, Kieseier B, Hartung HP: Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 33(3), 140-152 (2010).
3. Río J, Comabella M, Montalban X: Predicting responders to therapies for multiple sclerosis. Nat. Rev. Neurol. 5(10), 553-560 (2009).
4. Rudick RA, Polman CH: Current approaches to the identifcation and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 8(6), 545-559 (2009).
5. Hartung HP, Bar-Or A, Zoukos Y: What do we know about the mechanism of action of disease-modifying treatments in MS? J. Neurol. 251(Suppl. 5), v12-v29 (2004).
6. Dhib-Jalbut S, Marks S: Interferon-b mechanisms of action in multiple sclerosis. Neurology 74(Suppl. 1), S17-S24 (2010).
7. Racke MK, Lovett-Racke AE, Karandikar NJ: The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 74(Suppl. 1), S25-S30 (2010).
8. Vandenbroeck K, Comabella M, Tolosa E et al.: United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics 10(5), 885-894 (2009).
9. Bielekova B, Martin R: Development of biomarkers in multiple sclerosis. Brain 127(Pt 7), 1463-1478 (2004). (Pubitemid 38899400)
10. Goertsches RH, Hecker M, Zettl UK: Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks. J. Neurol. 255(Suppl. 6), 48-57 (2008).
11. Pascual V, Chaussabel D, Banchereau J: A genomic approach to human autoimmune diseases. Annu. Rev. Immunol. 28, 535-571 (2010).
12. Compston A, Coles A: Multiple sclerosis. Lancet 372(9648), 1502-1517 (2008).
13. Goverman J: Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9(6), 393-407 (2009).
14. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL: The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9(7), 516-526 (2008). (Pubitemid 351861542)
15. McFarland HF, Martin R: Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8(9), 913-919 (2007). (Pubitemid 47300005)
16. Gandhi R, Laroni A, Weiner HL: Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 221(1-2), 7-14 (2010).
17. Yu JJ, Gaffen SL: Interleukin-17: A novel infammatory cytokine that bridges innate and adaptive immunity. Front. Biosci. 13, 170-177 (2008). (Pubitemid 351594768)
18. Kebir H, Kreymborg K, Ifergan I et al.: Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system infammation. Nat. Med. 13(10), 1173-1175 (2007). (Pubitemid 47530640)
19. Du C, Liu C, Kang J et al.: MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 10(12), 1252-1259 (2009).
20. Durelli L, Conti L, Clerico M et al.: T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-b. Ann. Neurol. 65(5), 499-509 (2009).
21. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S: IFN-b inhibits human Th17 cell differentiation. J. Immunol. 183(8), 5418-5427 (2009).
22. Axtell RC, de Jong BA, Boniface K et al.: T helper type 1 and 17 cells determine effcacy of interferon-b in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16(4), 406-412 (2010).
23. Wekerle H, Hohlfeld R: Molecular oracles for multiple sclerosis therapy. Nat. Med. 16(4), 376-377 (2010).
24. Grossman I, Avidan N, Singer C et al.: Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet. Genomics 17(8), 657-666 (2007). (Pubitemid 47057715)
25. Byun E, Caillier SJ, Montalban X et al.: Genome-wide pharmacogenomic ana lysis of the response to interferon b therapy in multiple sclerosis. Arch. Neurol. 65(3), 337-344 (2008). (Pubitemid 351398518)
26. O'Doherty C, Favorov A, Heggarty S et al.: Genetic polymorphisms, their allele combinations and IFN-b treatment response in Irish multiple sclerosis patients. Pharmacogenomics 10(7), 1177-1186 (2009).
27. Cotte S, von Ahsen N, Kruse N et al.: ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132(Pt 9), 2517-2530 (2009).
28. Comabella M, Craig DW, Morcillo-Suárez C et al.: Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon b therapy in multiple sclerosis. Arch. Neurol. 66(8), 972-978 (2009).
29. Van Baarsen LG, Vosslamber S, Tijssen M et al.: Pharmacogenomics of interferon-b therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 3(4), e1927 (2008).
30. Achiron A, Feldman A, Gurevich M: Molecular profling of glatiramer acetate early treatment effects in multiple sclerosis. Dis. Markers 27(2), 63-73 (2009).
31. Goertsches R, Hecker M, Koczan D et al.: Long-term genome-wide blood RNA expression profles yield novel molecular response candidates for IFN-b-1b treatment in relapsing remitting MS. Pharmacogenomics 11(2), 147-161 (2010).
32. Baranzini SE, Mousavi P, Rio J et al.: Transcription-based prediction of response to IFNb using supervised computational methods. PLoS Biol. 3(1), e2 (2005).
33. Achiron A, Gurevich M, Snir Y et al.: Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis. Clin. Exp. Immunol. 149(2), 235-242 (2007). (Pubitemid 47063046)
34. Weinstock-Guttman B, Bhasi K, Badgett D et al.: Genomic effects of once-weekly, intramuscular interferon-b1 treatment after the frst dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J. Neuroimmunol. 205(1-2), 113-125 (2008).
35. Gurevich M, Tuller T, Rubinstein U et al.: Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med. Genomics 2, 46 (2009).
36. Comabella M, Lünemann JD, Río J et al.: A type I interferon signature in monocytes is associated with poor response to interferon-b in multiple sclerosis. Brain 132(Pt 12), 3353-3365 (2009).
37. Carroll WM: Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient beneft. Mult. Scler. 15(8), 951-958 (2009).
38. Reder AT, Ebers GC, Traboulsee A et al.: Cross-sectional study assessing long-term safety of interferon-b-1b for relapsing-remitting MS. Neurology 74(23), 1877-1885 (2010).
39. Van Der Voort LF, Gilli F, Bertolotto A et al.: Clinical effect of neutralizing antibodies to interferon b that persist long after cessation of therapy for multiple sclerosis. Arch. Neurol. 67(4), 402-407 (2010).
40. Steinman L: A brief history of T(H)17, the frst major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13(2), 139-145 (2007).
41. Holman DW, Klein RS, Ransohoff RM: The blood-brain barrier, chemokines and multiple sclerosis. Biochim. Biophys. Acta. 1812(2), 220-230 (2011).
42. Antonetti F, Finocchiaro O, Mascia M et al.: A comparison of the biologic activity of two recombinant IFN-b preparations used in the treatment of relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. 22(12), 1181-1184 (2002). (Pubitemid 36432854)
43. Markowitz CE: Interferon-b: mechanism of action and dosing issues. Neurology 68(Suppl. 4), S8-S11 (2007). (Pubitemid 46897272)
44. Gilli F, Marnetto F, Caldano M et al.: Biological responsiveness to frst injections of interferon-b in patients with multiple sclerosis. J. Neuroimmunol. 158(1-2), 195-203 (2005). (Pubitemid 39626087)
45. Reder AT, Velichko S, Yamaguchi KD et al.: IFN-b1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J. Interferon Cytokine Res. 28(5), 317-331 (2008). (Pubitemid 351725305)
46. Williams GJ, Witt PL: Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J. Interferon Cytokine Res. 18(11), 967-975 (1998). (Pubitemid 28565800)
47. Gilli F, Marnetto F, Caldano M H et al.: Biological markers of interferon-b therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler. 12(1), 47-57 (2006). (Pubitemid 43169237)
48. Weber MS, Prod'homme T, Youssef S et al.: Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13(8), 935-943 (2007). (Pubitemid 47222047)
49. Goertsches R, Hecker M, Thamilarasan M et al.: Dynamic ex vivo monocyte specifc and T cell relevant RNA signatures after glatiramer acetate administration in multiple sclerosis. J. Neuroimmunol. 228(1-2), 90; P539 (2010).
50. Borden EC, Sen GC, Uze G et al.: Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug. Discov. 6(12), 975-990 (2007). (Pubitemid 350201788)
51. Sellebjerg F, Krakauer M, Hesse D et al. Identification of new sensitive biomarkers for the in vivo response to interferon-p treatment in multiple sclerosis using DNA-array evaluation. Eur. J. Neurol. 16(12), 1291-1298 (2009).
52. Hesse D, Sellebjerg F, Sorensen PS: Absence of MxA induction by interferon p in patients with MS reflects complete loss of bioactivky. Neurology 73(5), 372-377 (2009).
53. Hecker M, Goertsches R, Fatum C et al. Network analysis of transcriptional regulation in response to intramuscular interferon p-la multiple sclerosis treatment. Pharmacogenomics J. (2010) (Epub ahead of print).
54. Morschhauser F, Marlton P, Vitolo U et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann. Oncol. 21(9), 1870-1876 (2010).
55. Singh MK, Scott TF, La Framboise WAet al.: Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing p-interferon therapy. Neurol. Sa. 258(1-2), 52-59 (2007). (Pubitemid 46874477)
56. Wandinger KP, Sturzebecher CS, Bielekova B et al.: Complex immunomodulatory effects of interferon-p in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 50(3), 349-357 (2001). (Pubitemid 32848737)
57. Iglesias AH, Camelo S, Hwang D, Villanueva R, Stephanopoulos G, Dangond F: Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 150(1-2), 163-177(2004). (Pubitemid 38481661)
58. Nelissen I, Martens E, Van den Steen PE et al. Gelatinase B/matrix met al.loproteinase-9 cleaves interferon-p and is a target for immunotherapy. Brain 126(Pt 6), 1371-1381 (2003). (Pubitemid 36644382)
59. Fainardi E, Castellazzi M, Bellini T et al. Cerebrospinal fluid and serum levels and intrathecal production of active matrix met al.loproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult. Scler. 12(3), 294-301 (2006). (Pubitemid 43827184)
60. Hesse D, Krakauer M, Lund H et al.Breakthrough disease during interferon-p therapy in MS: no signs of impaired biologic response. Neurology 74(18), 1455-1462 (2010).
61. KrumbholzM, Faber H, Steinmeyer F et al. Interferon-p increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131(Pt6), 1455-1463 (2008). (Pubitemid 351806460)
62. Gandhi KS, McKay FC, Schibeci SD et al. BAFF is a biological response marker to IFN-p treatment in multiple sclerosis. Interferon CytokineRes. 28(9), 529-539 (2008).
63. Pappas DJ, Coppola G, Gabatto PA et al. Longitudinal system-based analysis of transcriptional responses to type I interferons. Physiol. Genomics 38(3), 362-371 (2009).
64. Duda PW, Schmied MC, Cook SL et al. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. Clin. Invest. 105(7), 967-976 (2000). (Pubitemid 30203069)
65. Villoslada P, Steinman L, Baranzini SE: Systems biology and its application to the understanding of neurological diseases. Ann. Neurol. 65(2), 124-139 (2009).
66. Fernald GH, Knott S, Pachner A et al.: Genome-wide network analysis reveals the global properties of IFN-p immediate transcriptional effects in humans. Immunol. 178(8), 5076-5085 (2007). (Pubitemid 46595291)
67. Palacios R, Goni J, Martinez-Forero I et al.: A network analysis of the human T-cell activation gene network identifies JAGGEDl as a therapeutic target for autoimmune diseases. PLoS ONE 2, 222 (2007).
68. Yamaguchi KD, Ruderman DL, Croze E et al. IFN-p-regulated genes show abnormal expression in therapy-naive relapsing-remkting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. Neuroimmunol. 195(1-2), 116-120 (2008).
69. Sultan M, Schulz MH, Richard H et al.: A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science321(5891), 956-960 (2008).
70. Vosslamber S, Van Baarsen LG, Verweij CL: Pharmacogenomics of IFN-p in multiple sclerosis: towards a personalized medicine approach. Pharmacogenomics 10(1), 97-108 (2009).
71. Tingen CM, Kim AM, Wu PH, Woodruff TK: Sex and sensitivity: the continued need for sex-based biomedical research and implementation. Womens Health 6(4), 511-516 (2010).
72. Gandhi KS, McKay FC, Diefenbach E et al.: Novel approaches to detect serum biomarkers for clinical response to interferon-p treatment in multiple sclerosis. PLoS ONE 5 (5), e 10484 (2010).
73. Rudick R, Kappos L, Kinkel R et al.: Gender effects on intramuscular interferon p-la in relapsing-remkting multiple sclerosis: analysis of 1406 patients. Mult. Scler. (2010) (Epub ahead of print).
74. Weinstock-Guttman B, Badgett D, Patrick K et al.: Genomic effects of IFN-p in multiple sclerosis patients. Immunol. 171(5), 2694-2702 (2003). (Pubitemid 37025583)
75. Santos R, Weinstock-Guttman B, Tamano-Blanco M et al.: Dynamics of interferon-p modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-p neutralizing antibodies. Neuroimmunol. 176(1-2), 125-133 (2006). (Pubitemid 44080329)
76. Hesse D, Krakauer M, Lund H et al.: Disease protection and interleukin-10 induction by endogenous interferon-p in multiple sclerosis? Eur. J. Neurol, doi: 18, 266-272 (2010) (Epub ahead of print).
77. Sellebjerg F, Datta P, Larsen J et al.: Gene expression analysis of interferon-p treatment in multiple sclerosis. Mult. Scler. 14(5), 615-621 (2008). (Pubitemid 351954403)
78. Satoh J, Nakanishi M, Koike F et al.: T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. Neuroimmunol. 174(1-2), 108-118 (2006).
79. Koike F, Satoh J, Miyake S et al.: Microarray analysis identifies interferon p-regulated genes in multiple sclerosis. Neuroimmunol. 139(1-2), 109-118 (2003). (Pubitemid 36694397)
80. Sturzebecher S, Wandinger KP, Rosenwald A et al.: Expression profiling identifies responder and non-responder phenotypes to interferon-p in multiple sclerosis. Brain 126(6), 1419-1429 (2003). (Pubitemid 36644386)
81. Annibali V, Di Giavanni S, Cannoni S et al.: Gene expression profiles reveal homeostatic dynamics during interferon-p therapy in multiple sclerosis. Autoimmunity 40(1), 16-22 (2007). (Pubitemid 46332418)